141286-84-2

Upstream product

• 105-36-2 ethyl bromoacetate 
• 169298-43-5 N-<2-(3,5-difluoro-4-hydroxyphenylthio)ethyl>phthalimide 
• 28177-48-2 2,6-difluorophenol 
• 151389-58-1 2,6-difluoro-4-mercaptophenol 
• 539-74-2 Ethyl 3-bromopropionate 
• 151389-57-0 3,5-difluoro-4-hydroxybenzenesulfonyl chloride 
• 574-98-1 2-(2-bromoethyl)isoindoline-1,3-dione 

Relevant academic research and scientific papers

PROPHYLACTIC AND/OR THERAPEUTIC AGENT FOR DISEASES ASSOCIATED WITH AMPA RECEPTORS

This prophylactic and/or therapeutic agent for diseases associated with AMPA receptors contains a compound represented by formula (I), or a pharmaceutically acceptable salt or solvate thereof. (In the formula, A and Z independently represent CO, SO or SO

In vivo AMPA receptors in the brain imaging method of primates, program, and screening method

This imaging method of AMPA receptors in the brain of primate organisms involves a step in which a substance which is administered to the primate organism and which selectively bonds to AMPA receptors in the brain of the primate organism and has a radiola

Synthesis and evaluation of novel fluorinated sulotroban-related sulfonamide derivatives as thromboxane A2 receptor antagonists

A series of sulotroban-related arylsulfonamide derivatives possessing a fluorinated phenoxyacetic acid moiety was synthesized and tested for TXA2 antagonizing ability on U-46619-induced platelet aggregation of rabbit platelet-rich plasma. Introduction of one or more fluorine atoms to the phenoxyacetic acid moiety increased this activity. The most potent compound among these compounds was 10c, which was 40-fold more potent (IC50 3.4 x 10-7 M) than sulotroban. 10c exhibited high activity (ID50 0.14 mg/kg) against a D-46619-induced acute thrombocytopenia model in mice when orally administrated. These findings and those of radioligand binding assays with various ligands showed 10c to be a potent and selective systemic TXA2 receptor antagonist.